Tivantinib is a selective oral inhibitor of MET that has now been tested in a phase II trial in patients with unresectable hepatocellular carcinoma. Compared with the placebo control, treatment with tivantinib significantly benefitted patients whose disease had progressed on first-line therapy, especially those patients who were determined to be MET positive by immunohistochemical analysis. A manageable safety profile was reported.